Trial Outcomes & Findings for Efficacy and Safety of RTH258 Versus Aflibercept - Study 2 (NCT NCT02434328)

NCT ID: NCT02434328

Last Updated: 2025-01-16

Results Overview

BCVA (with spectacles or other visual corrective devices) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 1048 participants
• Primary outcome timeframe: Baseline, Week 48
• Results posted on: 2025-01-16

Participant Flow

Subjects were recruited from investigative sites located in Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, South Korea, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Russia, Singapore, Slovakia, Spain, Switzerland, Taiwan, Turkey, UK, and Vietnam.

Of the 1048 subjects enrolled in the study, 305 were exited prior to randomization as screen failures. This reporting group includes all randomized subjects.

Participant milestones

Measure	Brolucizumab 6 mg Single intravitreal (IVT) injection of brolucizumab at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Aflibercept 2 mg Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Overall Study STARTED	372	371
Overall Study Randomized and Treated	370	369
Overall Study COMPLETED	342	329
Overall Study NOT COMPLETED	30	42

Reasons for withdrawal

Measure	Brolucizumab 6 mg Single intravitreal (IVT) injection of brolucizumab at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Aflibercept 2 mg Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Overall Study Adverse Event	9	4
Overall Study Lack of Efficacy	0	2
Overall Study Physician Decision	0	1
Overall Study Withdrawal by Subject	12	21
Overall Study Death	4	7
Overall Study Lost to Follow-up	1	6
Overall Study Other	4	1

Baseline Characteristics

Efficacy and Safety of RTH258 Versus Aflibercept - Study 2

Baseline characteristics by cohort

Measure	Brolucizumab 6 mg n=370 Participants Single intravitreal (IVT) injection of brolucizumab at Day 0, Week 4, and Week 8, followed by 1 injection every 8 weeks/1 injection every 12 weeks (q8w/q12w) maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit	Total n=739 Participants Total of all reporting groups
Age, Continuous	74.8 years STANDARD_DEVIATION 8.58 • n=5 Participants	75.5 years STANDARD_DEVIATION 7.87 • n=7 Participants	75.1 years STANDARD_DEVIATION 8.24 • n=5 Participants
Age, Customized less than 50 years	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants
Age, Customized 50-64 years	44 participants n=5 Participants	28 participants n=7 Participants	72 participants n=5 Participants
Age, Customized 65-74 years	124 participants n=5 Participants	126 participants n=7 Participants	250 participants n=5 Participants
Age, Customized 75-84 years	150 participants n=5 Participants	167 participants n=7 Participants	317 participants n=5 Participants
Age, Customized 85 years and greater	52 participants n=5 Participants	48 participants n=7 Participants	100 participants n=5 Participants
Sex: Female, Male Female	210 Participants n=5 Participants	212 Participants n=7 Participants	422 Participants n=5 Participants
Sex: Female, Male Male	160 Participants n=5 Participants	157 Participants n=7 Participants	317 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	23 Participants n=5 Participants	25 Participants n=7 Participants	48 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	321 Participants n=5 Participants	322 Participants n=7 Participants	643 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	26 Participants n=5 Participants	22 Participants n=7 Participants	48 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Asian	22 Participants n=5 Participants	23 Participants n=7 Participants	45 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants
Race (NIH/OMB) White	340 Participants n=5 Participants	341 Participants n=7 Participants	681 Participants n=5 Participants
Race (NIH/OMB) More than one race	2 Participants n=5 Participants	1 Participants n=7 Participants	3 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	5 Participants n=5 Participants	4 Participants n=7 Participants	9 Participants n=5 Participants
Best Corrected Visual Acuity (BCVA) (letters read)	61.5 letters STANDARD_DEVIATION 12.59 • n=5 Participants	60.8 letters STANDARD_DEVIATION 12.93 • n=7 Participants	61.2 letters STANDARD_DEVIATION 12.76 • n=5 Participants

PRIMARY outcome

Timeframe: Baseline, Week 48

Population: Full Analysis Set (FAS) - Last Observation Carried Forward (LOCF)

BCVA (with spectacles or other visual corrective devices) was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Change From Baseline in Best Corrected Visual Acuity (BCVA) (Letters Read) at Week 48 - Study Eye	6.9 letters Standard Deviation 11.47	7.6 letters Standard Deviation 12.47

SECONDARY outcome

Timeframe: Baseline, Weeks 36, 40, 44, 48

Population: FAS - LOCF

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. For each subject, this endpoint was defined as the average of the changes from baseline to Weeks 36, 40, 44, and 48. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Average Change From Baseline in BCVA (Letters Read) Over the Period Week 36 Through Week 48 - Study Eye	6.6 letters Standard Deviation 11.10	7.7 letters Standard Deviation 11.81

SECONDARY outcome

Timeframe: Weeks 16, 20, 28, 32, 40, 44, 48

Population: FAS - efficacy/safety approach

Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w (one injection every 8 weeks) need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% Confidence Intervals (CIs) were derived from the LOGLOG transformation. This outcome measure was pre-specified for brolucizumab 6 mg arm only. Hypothesis testing not pre-specified.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Proportion of Subjects With Positive q12 (Every 12 Weeks) Treatment Status at Week 48	0.5101 proportion of subjects Interval 0.4567 to 0.561	—

SECONDARY outcome

Timeframe: Weeks 16, 20, 28, 32, 40, 44, 48

Population: FAS - efficacy/safety approach

Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% Confidence Intervals (CIs) were derived from the LOGLOG transformation. This outcome measure was pre-specified for brolucizumab 6 mg arm only. Hypothesis testing not pre-specified.

Outcome measures

Measure	Brolucizumab 6 mg n=220 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Proportion of Subjects With Positive q12 Treatment Status at Week 48 Within the Subjects With no q8 (Every 8 Weeks) Treatment Need During the Initial q12w Cycle (Week 16, Week 20)	0.8170 proportion of subjects Interval 0.7582 to 0.8629	—

SECONDARY outcome

Timeframe: Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96

Population: FAS - efficacy/safety approach

Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% Confidence Intervals (CIs) were derived from the LOGLOG transformation. This outcome measure was pre-specified for brolucizumab 6 mg arm only. Hypothesis testing not pre-specified.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Proportion of Subjects With Positive q12 Treatment Status up to Week 96	0.3856 proportion of subjects Interval 0.3336 to 0.4372	—

SECONDARY outcome

Timeframe: Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92, 96

Population: FAS - efficacy/safety approach

Positive q12 treatment status was defined as IVT injections per planned dosing regimen (one injection every 12 weeks "q12w", after the initial three loading injections every 4 weeks "q4w"). A disease activity assessment (DAA) was performed at pre-specified visits (Weeks 16, 20, 28, 32, 40, 44, 52, 56, 64, 68, 76, 80, 88, 92) to identify q8w need. The estimate for the proportion of subjects with a positive q12w status at Week 48 were derived from Kaplan-Meier time to event analyses for the event of first q8w need, applying event allocations (in case of lack of efficacy and/or lack of safety=efficacy/safety approach) and censoring as described in the SAP. Censored subjects were considered to be not anymore under risk for a q8 need identification at later visits. Corresponding 95% Confidence Intervals (CIs) were derived from the LOGLOG transformation. This outcome measure was pre-specified for brolucizumab 6 mg arm only. Hypothesis testing not pre-specified.

Outcome measures

Measure	Brolucizumab 6 mg n=221 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Proportion of Subjects With Positive q12 Treatment Status at Week 96 Within the Subjects With no q8 Treatment Need During the Initial q12w Cycle (Week 16, Week 20)	0.6170 proportion of subjects Interval 0.5465 to 0.6799	—

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 72	6.1 letters Standard Deviation 13.32	6.9 letters Standard Deviation 13.74
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 84	5.8 letters Standard Deviation 13.76	6.7 letters Standard Deviation 14.04
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 88	6.3 letters Standard Deviation 13.40	6.9 letters Standard Deviation 14.02
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 92	6.1 letters Standard Deviation 13.85	6.5 letters Standard Deviation 14.29
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 4	3.7 letters Standard Deviation 7.03	4.7 letters Standard Deviation 7.62
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 8	5.0 letters Standard Deviation 8.16	6.0 letters Standard Deviation 9.32
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 12	5.4 letters Standard Deviation 9.35	6.4 letters Standard Deviation 10.14
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 16	5.4 letters Standard Deviation 9.65	6.3 letters Standard Deviation 10.46
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 20	5.4 letters Standard Deviation 10.42	6.9 letters Standard Deviation 10.66
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 24	5.8 letters Standard Deviation 10.76	6.7 letters Standard Deviation 11.17
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 28	6.3 letters Standard Deviation 10.97	7.4 letters Standard Deviation 11.86
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 32	6.5 letters Standard Deviation 10.92	7.3 letters Standard Deviation 11.44
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 36	6.4 letters Standard Deviation 11.32	7.6 letters Standard Deviation 11.99
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 40	6.4 letters Standard Deviation 11.66	7.6 letters Standard Deviation 11.85
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 44	6.5 letters Standard Deviation 11.51	8.0 letters Standard Deviation 12.28
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 48	6.9 letters Standard Deviation 11.47	7.6 letters Standard Deviation 12.47
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 52	6.8 letters Standard Deviation 12.03	7.4 letters Standard Deviation 12.91
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 56	6.6 letters Standard Deviation 12.43	7.2 letters Standard Deviation 13.04
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 60	6.5 letters Standard Deviation 12.23	7.4 letters Standard Deviation 13.49
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 64	6.5 letters Standard Deviation 12.51	7.2 letters Standard Deviation 13.79
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 68	6.5 letters Standard Deviation 12.22	7.1 letters Standard Deviation 14.29
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 76	6.3 letters Standard Deviation 13.44	6.8 letters Standard Deviation 13.80
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 80	6.4 letters Standard Deviation 13.43	6.6 letters Standard Deviation 13.97
Change From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 96	6.1 letters Standard Deviation 14.06	6.6 letters Standard Deviation 14.55

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Average Change From Baseline in BCVA (Letters Read) Over the Period Week 4 to Week 48/96 - Study Eye Change from baseline over the period Week 4 to 48	5.8 letters Standard Deviation 9.11	6.9 letters Standard Deviation 10.11
Average Change From Baseline in BCVA (Letters Read) Over the Period Week 4 to Week 48/96 - Study Eye Change from baseline over the period Week 4 to 96	6.1 letters Standard Deviation 10.42	6.9 letters Standard Deviation 11.41

SECONDARY outcome

Timeframe: Baseline, Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Average Change From Baseline in BCVA (Letters Read) Over the Period Week 12 to Week 48/96 - Study Eye Change from baseline over the period Week 12 to 48	6.1 letters Standard Deviation 9.91	7.2 letters Standard Deviation 10.77
Average Change From Baseline in BCVA (Letters Read) Over the Period Week 12 to Week 48/96 - Study Eye Change from baseline over the period Week 12 to 96	6.2 letters Standard Deviation 10.97	7.0 letters Standard Deviation 11.88

SECONDARY outcome

Timeframe: Baseline, Weeks 84, 88, 92, 96

Population: FAS - LOCF

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Average Change From Baseline in BCVA (Letters Read) Over the Period Week 84 to Week 96 - Study Eye	6.1 letters Standard Deviation 13.51	6.7 letters Standard Deviation 13.96

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 4	7.6 percentage of subjects Interval 5.1 to 10.8	8.9 percentage of subjects Interval 6.2 to 12.3
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 8	13.8 percentage of subjects Interval 10.4 to 17.7	18.2 percentage of subjects Interval 14.4 to 22.5
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 12	16.5 percentage of subjects Interval 12.9 to 20.7	21.4 percentage of subjects Interval 17.3 to 26.0
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 24	23.8 percentage of subjects Interval 19.5 to 28.5	22.8 percentage of subjects Interval 18.6 to 27.4
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 28	23.8 percentage of subjects Interval 19.5 to 28.5	27.4 percentage of subjects Interval 22.9 to 32.2
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 32	25.4 percentage of subjects Interval 21.0 to 30.2	28.7 percentage of subjects Interval 24.2 to 33.6
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 56	29.7 percentage of subjects Interval 25.1 to 34.7	30.6 percentage of subjects Interval 26.0 to 35.6
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 60	28.6 percentage of subjects Interval 24.1 to 33.5	30.6 percentage of subjects Interval 26.0 to 35.6
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 64	29.7 percentage of subjects Interval 25.1 to 34.7	30.9 percentage of subjects Interval 26.2 to 35.9
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 68	28.9 percentage of subjects Interval 24.3 to 33.8	32.2 percentage of subjects Interval 27.5 to 37.3
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 80	28.1 percentage of subjects Interval 23.6 to 33.0	30.4 percentage of subjects Interval 25.7 to 35.3
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 88	27.6 percentage of subjects Interval 23.1 to 32.4	33.1 percentage of subjects Interval 28.3 to 38.1
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 92	29.5 percentage of subjects Interval 24.9 to 34.4	30.9 percentage of subjects Interval 26.2 to 35.9
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 96	29.2 percentage of subjects Interval 24.6 to 34.1	31.4 percentage of subjects Interval 26.7 to 36.4
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 72	27.6 percentage of subjects Interval 23.1 to 32.4	31.4 percentage of subjects Interval 26.7 to 36.4
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 76	28.4 percentage of subjects Interval 23.8 to 33.3	30.6 percentage of subjects Interval 26.0 to 35.6
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 84	27.6 percentage of subjects Interval 23.1 to 32.4	31.2 percentage of subjects Interval 26.5 to 36.2
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 16	20.0 percentage of subjects Interval 16.0 to 24.4	22.2 percentage of subjects Interval 18.1 to 26.8
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 20	20.5 percentage of subjects Interval 16.5 to 25.0	23.6 percentage of subjects Interval 19.3 to 28.2
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 36	26.2 percentage of subjects Interval 21.8 to 31.0	30.9 percentage of subjects Interval 26.2 to 35.9
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 40	27.0 percentage of subjects Interval 22.6 to 31.9	31.4 percentage of subjects Interval 26.7 to 36.4
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 44	26.8 percentage of subjects Interval 22.3 to 31.6	31.2 percentage of subjects Interval 26.5 to 36.2
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 48	29.5 percentage of subjects Interval 24.9 to 34.4	29.8 percentage of subjects Interval 25.2 to 34.8
Percentage of Subjects With >=15 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 52	30.3 percentage of subjects Interval 25.6 to 35.2	30.6 percentage of subjects Interval 26.0 to 35.6

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 84	40.8 percentage of subjects Interval 35.8 to 46.0	44.2 percentage of subjects Interval 39.0 to 49.4
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 12	32.4 percentage of subjects Interval 27.7 to 37.5	36.0 percentage of subjects Interval 31.1 to 41.2
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 20	33.8 percentage of subjects Interval 29.0 to 38.9	38.2 percentage of subjects Interval 33.2 to 43.4
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 24	35.7 percentage of subjects Interval 30.8 to 40.8	39.3 percentage of subjects Interval 34.3 to 44.5
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 28	40.3 percentage of subjects Interval 35.2 to 45.5	42.5 percentage of subjects Interval 37.4 to 47.8
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 32	41.1 percentage of subjects Interval 36.0 to 46.3	43.4 percentage of subjects Interval 38.2 to 48.6
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 36	40.3 percentage of subjects Interval 35.2 to 45.5	45.5 percentage of subjects Interval 40.4 to 50.8
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 40	43.5 percentage of subjects Interval 38.4 to 48.7	46.3 percentage of subjects Interval 41.2 to 51.6
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 44	42.4 percentage of subjects Interval 37.3 to 47.6	45.3 percentage of subjects Interval 40.1 to 50.5
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 48	44.1 percentage of subjects Interval 38.9 to 49.3	45.8 percentage of subjects Interval 40.6 to 51.0
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 52	44.9 percentage of subjects Interval 39.7 to 50.1	45.8 percentage of subjects Interval 40.6 to 51.0
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 56	43.0 percentage of subjects Interval 37.9 to 48.2	45.5 percentage of subjects Interval 40.4 to 50.8
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 60	42.2 percentage of subjects Interval 37.1 to 47.4	44.7 percentage of subjects Interval 39.6 to 49.9
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 68	43.5 percentage of subjects Interval 38.4 to 48.7	45.0 percentage of subjects Interval 39.8 to 50.2
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 72	41.1 percentage of subjects Interval 36.0 to 46.3	44.4 percentage of subjects Interval 39.3 to 49.7
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 76	45.4 percentage of subjects Interval 40.3 to 50.6	44.7 percentage of subjects Interval 39.6 to 49.9
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 80	43.8 percentage of subjects Interval 38.7 to 49.0	44.2 percentage of subjects Interval 39.0 to 49.4
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 92	45.4 percentage of subjects Interval 40.3 to 50.6	43.4 percentage of subjects Interval 38.2 to 48.6
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 4	20.0 percentage of subjects Interval 16.0 to 24.4	22.2 percentage of subjects Interval 18.1 to 26.8
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 8	26.8 percentage of subjects Interval 22.3 to 31.6	32.8 percentage of subjects Interval 28.0 to 37.8
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 16	36.5 percentage of subjects Interval 31.6 to 41.6	36.9 percentage of subjects Interval 31.9 to 42.0
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 64	44.3 percentage of subjects Interval 39.2 to 49.5	45.8 percentage of subjects Interval 40.6 to 51.0
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 88	43.2 percentage of subjects Interval 38.1 to 48.5	45.5 percentage of subjects Interval 40.4 to 50.8
Percentage of Subjects With >=10 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 96	45.1 percentage of subjects Interval 40.0 to 50.4	45.0 percentage of subjects Interval 39.8 to 50.2

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 8	50.0 percentage of subjects Interval 44.8 to 55.2	53.1 percentage of subjects Interval 47.9 to 58.3
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 16	55.4 percentage of subjects Interval 50.2 to 60.5	56.6 percentage of subjects Interval 51.4 to 61.8
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 28	60.0 percentage of subjects Interval 54.8 to 65.0	65.6 percentage of subjects Interval 60.5 to 70.4
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 32	64.1 percentage of subjects Interval 58.9 to 68.9	65.6 percentage of subjects Interval 60.5 to 70.4
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 36	63.2 percentage of subjects Interval 58.1 to 68.2	65.3 percentage of subjects Interval 60.2 to 70.2
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 48	64.6 percentage of subjects Interval 59.5 to 69.5	64.5 percentage of subjects Interval 59.4 to 69.4
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 60	62.2 percentage of subjects Interval 57.0 to 67.1	62.6 percentage of subjects Interval 57.4 to 67.6
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 64	65.7 percentage of subjects Interval 60.6 to 70.5	63.1 percentage of subjects Interval 58.0 to 68.1
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 68	62.2 percentage of subjects Interval 57.0 to 67.1	63.4 percentage of subjects Interval 58.3 to 68.3
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 72	63.0 percentage of subjects Interval 57.8 to 67.9	61.5 percentage of subjects Interval 56.3 to 66.5
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 76	63.8 percentage of subjects Interval 58.7 to 68.7	61.5 percentage of subjects Interval 56.3 to 66.5
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 80	65.1 percentage of subjects Interval 60.0 to 70.0	60.7 percentage of subjects Interval 55.5 to 65.7
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 84	61.9 percentage of subjects Interval 56.7 to 66.9	64.2 percentage of subjects Interval 59.1 to 69.1
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 88	63.2 percentage of subjects Interval 58.1 to 68.2	62.1 percentage of subjects Interval 56.9 to 67.0
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 92	64.6 percentage of subjects Interval 59.5 to 69.5	60.7 percentage of subjects Interval 55.5 to 65.7
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 96	64.1 percentage of subjects Interval 58.9 to 68.9	60.7 percentage of subjects Interval 55.5 to 65.7
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 4	41.6 percentage of subjects Interval 36.5 to 46.8	45.3 percentage of subjects Interval 40.1 to 50.5
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 12	55.1 percentage of subjects Interval 49.9 to 60.3	58.5 percentage of subjects Interval 53.3 to 63.6
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 20	55.9 percentage of subjects Interval 50.7 to 61.1	61.0 percentage of subjects Interval 55.8 to 66.0
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 24	58.1 percentage of subjects Interval 52.9 to 63.2	61.0 percentage of subjects Interval 55.8 to 66.0
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 40	63.0 percentage of subjects Interval 57.8 to 67.9	64.0 percentage of subjects Interval 58.8 to 68.9
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 44	64.6 percentage of subjects Interval 59.5 to 69.5	65.9 percentage of subjects Interval 60.8 to 70.7
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 52	63.0 percentage of subjects Interval 57.8 to 67.9	65.3 percentage of subjects Interval 60.2 to 70.2
Percentage of Subjects With >=5 Letter Gain From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 56	62.7 percentage of subjects Interval 57.6 to 67.6	64.2 percentage of subjects Interval 59.1 to 69.1

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 20	3.5 percentage of subjects Interval 1.9 to 5.9	3.0 percentage of subjects Interval 1.5 to 5.3
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 24	2.7 percentage of subjects Interval 1.3 to 4.9	3.3 percentage of subjects Interval 1.7 to 5.6
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 32	3.2 percentage of subjects Interval 1.7 to 5.6	3.8 percentage of subjects Interval 2.1 to 6.3
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 48	3.8 percentage of subjects Interval 2.1 to 6.3	4.9 percentage of subjects Interval 2.9 to 7.6
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 4	1.1 percentage of subjects Interval 0.3 to 2.7	1.1 percentage of subjects Interval 0.3 to 2.8
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 8	1.1 percentage of subjects Interval 0.3 to 2.7	1.6 percentage of subjects Interval 0.6 to 3.5
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 12	1.9 percentage of subjects Interval 0.8 to 3.9	1.9 percentage of subjects Interval 0.8 to 3.9
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 16	2.2 percentage of subjects Interval 0.9 to 4.2	2.2 percentage of subjects Interval 0.9 to 4.2
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 28	3.0 percentage of subjects Interval 1.5 to 5.3	3.5 percentage of subjects Interval 1.9 to 5.9
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 36	3.8 percentage of subjects Interval 2.1 to 6.3	3.5 percentage of subjects Interval 1.9 to 5.9
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 40	5.4 percentage of subjects Interval 3.3 to 8.2	4.3 percentage of subjects Interval 2.5 to 6.9
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 44	4.6 percentage of subjects Interval 2.7 to 7.3	4.6 percentage of subjects Interval 2.7 to 7.3
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 52	4.6 percentage of subjects Interval 2.7 to 7.3	5.7 percentage of subjects Interval 3.6 to 8.6
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 56	5.9 percentage of subjects Interval 3.8 to 8.9	5.4 percentage of subjects Interval 3.3 to 8.2
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 64	6.8 percentage of subjects Interval 4.4 to 9.8	6.2 percentage of subjects Interval 4.0 to 9.2
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 72	7.3 percentage of subjects Interval 4.9 to 10.4	6.5 percentage of subjects Interval 4.2 to 9.5
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 92	7.0 percentage of subjects Interval 4.6 to 10.1	7.6 percentage of subjects Interval 5.1 to 10.8
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 96	7.0 percentage of subjects Interval 4.6 to 10.1	7.6 percentage of subjects Interval 5.1 to 10.8
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 60	6.2 percentage of subjects Interval 4.0 to 9.2	5.7 percentage of subjects Interval 3.6 to 8.6
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 68	5.4 percentage of subjects Interval 3.3 to 8.2	6.5 percentage of subjects Interval 4.2 to 9.5
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 76	6.8 percentage of subjects Interval 4.4 to 9.8	6.2 percentage of subjects Interval 4.0 to 9.2
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 80	7.0 percentage of subjects Interval 4.6 to 10.1	6.2 percentage of subjects Interval 4.0 to 9.2
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 84	7.3 percentage of subjects Interval 4.9 to 10.4	7.3 percentage of subjects Interval 4.9 to 10.5
Percentage of Subjects With >=15 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 88	6.8 percentage of subjects Interval 4.4 to 9.8	7.0 percentage of subjects Interval 4.7 to 10.2

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 92	9.2 percentage of subjects Interval 6.4 to 12.6	11.1 percentage of subjects Interval 8.1 to 14.8
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 52	8.1 percentage of subjects Interval 5.5 to 11.4	7.3 percentage of subjects Interval 4.9 to 10.5
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 96	9.2 percentage of subjects Interval 6.4 to 12.6	10.3 percentage of subjects Interval 7.4 to 13.9
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 56	9.2 percentage of subjects Interval 6.4 to 12.6	8.1 percentage of subjects Interval 5.6 to 11.4
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 60	8.1 percentage of subjects Interval 5.5 to 11.4	7.3 percentage of subjects Interval 4.9 to 10.5
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 64	8.4 percentage of subjects Interval 5.8 to 11.7	8.7 percentage of subjects Interval 6.0 to 12.0
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 68	7.6 percentage of subjects Interval 5.1 to 10.8	8.4 percentage of subjects Interval 5.8 to 11.7
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 72	7.8 percentage of subjects Interval 5.3 to 11.1	8.1 percentage of subjects Interval 5.6 to 11.4
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 80	9.2 percentage of subjects Interval 6.4 to 12.6	10.0 percentage of subjects Interval 7.2 to 13.6
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 20	5.9 percentage of subjects Interval 3.8 to 8.9	4.6 percentage of subjects Interval 2.7 to 7.3
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 24	5.1 percentage of subjects Interval 3.1 to 7.9	6.0 percentage of subjects Interval 3.8 to 8.9
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 28	5.9 percentage of subjects Interval 3.8 to 8.9	5.7 percentage of subjects Interval 3.6 to 8.6
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 32	5.9 percentage of subjects Interval 3.8 to 8.9	6.2 percentage of subjects Interval 4.0 to 9.2
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 36	6.5 percentage of subjects Interval 4.2 to 9.5	6.2 percentage of subjects Interval 4.0 to 9.2
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 40	7.0 percentage of subjects Interval 4.6 to 10.1	6.0 percentage of subjects Interval 3.8 to 8.9
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 44	8.6 percentage of subjects Interval 6.0 to 12.0	6.2 percentage of subjects Interval 4.0 to 9.2
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 48	6.8 percentage of subjects Interval 4.4 to 9.8	7.3 percentage of subjects Interval 4.9 to 10.5
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 84	9.5 percentage of subjects Interval 6.7 to 12.9	9.5 percentage of subjects Interval 6.7 to 12.9
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 88	8.9 percentage of subjects Interval 6.2 to 12.3	9.8 percentage of subjects Interval 6.9 to 13.3
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 76	9.5 percentage of subjects Interval 6.7 to 12.9	9.2 percentage of subjects Interval 6.5 to 12.6
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 4	1.9 percentage of subjects Interval 0.8 to 3.9	2.4 percentage of subjects Interval 1.1 to 4.6
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 8	2.2 percentage of subjects Interval 0.9 to 4.2	2.2 percentage of subjects Interval 0.9 to 4.2
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 16	3.8 percentage of subjects Interval 2.1 to 6.3	5.1 percentage of subjects Interval 3.1 to 7.9
Percentage of Subjects With >=10 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 12	2.7 percentage of subjects Interval 1.3 to 4.9	3.0 percentage of subjects Interval 1.5 to 5.3

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly. Baseline was defined as the last measurement prior to first treatment. An increase (gain) in letters read from the baseline assessment indicates improvement. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 4	6.2 percentage of subjects Interval 4.0 to 9.2	6.5 percentage of subjects Interval 4.2 to 9.5
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 8	7.8 percentage of subjects Interval 5.3 to 11.1	8.4 percentage of subjects Interval 5.8 to 11.7
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 12	8.4 percentage of subjects Interval 5.8 to 11.7	9.5 percentage of subjects Interval 6.7 to 12.9
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 16	10.8 percentage of subjects Interval 7.8 to 14.4	8.9 percentage of subjects Interval 6.2 to 12.3
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 20	11.6 percentage of subjects Interval 8.5 to 15.3	8.1 percentage of subjects Interval 5.6 to 11.4
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 24	13.0 percentage of subjects Interval 9.7 to 16.8	10.0 percentage of subjects Interval 7.2 to 13.6
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 28	11.4 percentage of subjects Interval 8.3 to 15.0	8.9 percentage of subjects Interval 6.2 to 12.3
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 32	12.2 percentage of subjects Interval 9.0 to 15.9	11.1 percentage of subjects Interval 8.1 to 14.8
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 36	12.7 percentage of subjects Interval 9.5 to 16.5	9.5 percentage of subjects Interval 6.7 to 12.9
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 40	11.9 percentage of subjects Interval 8.8 to 15.6	11.1 percentage of subjects Interval 8.1 to 14.8
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 44	11.9 percentage of subjects Interval 8.8 to 15.6	9.2 percentage of subjects Interval 6.5 to 12.6
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 48	11.1 percentage of subjects Interval 8.1 to 14.7	11.9 percentage of subjects Interval 8.8 to 15.7
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 52	13.2 percentage of subjects Interval 10.0 to 17.1	11.4 percentage of subjects Interval 8.3 to 15.1
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 80	13.8 percentage of subjects Interval 10.4 to 17.7	15.2 percentage of subjects Interval 11.7 to 19.3
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 88	13.0 percentage of subjects Interval 9.7 to 16.8	14.4 percentage of subjects Interval 10.9 to 18.4
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 92	14.3 percentage of subjects Interval 10.9 to 18.3	16.0 percentage of subjects Interval 12.4 to 20.1
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 96	14.3 percentage of subjects Interval 10.9 to 18.3	14.6 percentage of subjects Interval 11.2 to 18.7
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 56	13.2 percentage of subjects Interval 10.0 to 17.1	11.7 percentage of subjects Interval 8.6 to 15.4
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 60	12.7 percentage of subjects Interval 9.5 to 16.5	11.7 percentage of subjects Interval 8.6 to 15.4
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 64	12.7 percentage of subjects Interval 9.5 to 16.5	12.5 percentage of subjects Interval 9.3 to 16.3
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 68	13.8 percentage of subjects Interval 10.4 to 17.7	12.2 percentage of subjects Interval 9.0 to 16.0
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 72	14.1 percentage of subjects Interval 10.7 to 18.0	13.6 percentage of subjects Interval 10.2 to 17.5
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 76	14.1 percentage of subjects Interval 10.7 to 18.0	13.6 percentage of subjects Interval 10.2 to 17.5
Percentage of Subjects With >=5 Letter Loss From Baseline in BCVA (Letters Read) at Each Post-baseline Visit - Study Eye Change from baseline at Week 84	14.1 percentage of subjects Interval 10.7 to 18.0	14.6 percentage of subjects Interval 11.2 to 18.7

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

BCVA (with spectacles or other visual corrective devices) was assessed using ETDRS testing at 4 meters and reported in letters read correctly (0-100 letters). A score of 65 to 70 letters represents a low to moderate visual acuity. Baseline was defined as the last measurement prior to first treatment. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 24	45.4 percentage of subjects Interval 40.3 to 50.6	47.4 percentage of subjects Interval 42.2 to 52.7
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 28	48.6 percentage of subjects Interval 43.4 to 53.9	50.4 percentage of subjects Interval 45.2 to 55.6
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 12	43.5 percentage of subjects Interval 38.4 to 48.7	44.7 percentage of subjects Interval 39.6 to 49.9
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 16	44.1 percentage of subjects Interval 38.9 to 49.3	42.5 percentage of subjects Interval 37.4 to 47.8
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 32	47.8 percentage of subjects Interval 42.6 to 53.1	49.6 percentage of subjects Interval 44.4 to 54.8
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 44	50.3 percentage of subjects Interval 45.1 to 55.5	50.4 percentage of subjects Interval 45.2 to 55.6
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 60	48.9 percentage of subjects Interval 43.7 to 54.1	52.3 percentage of subjects Interval 47.1 to 57.5
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 92	50.5 percentage of subjects Interval 45.3 to 55.7	49.9 percentage of subjects Interval 44.6 to 55.1
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Baseline	21.4 percentage of subjects Interval 17.3 to 25.9	17.9 percentage of subjects Interval 14.1 to 22.2
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 36	47.6 percentage of subjects Interval 42.4 to 52.8	49.9 percentage of subjects Interval 44.6 to 55.1
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 4	31.9 percentage of subjects Interval 27.2 to 36.9	34.7 percentage of subjects Interval 29.8 to 39.8
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 8	40.3 percentage of subjects Interval 35.2 to 45.5	41.2 percentage of subjects Interval 36.1 to 46.4
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 40	48.9 percentage of subjects Interval 43.7 to 54.1	49.3 percentage of subjects Interval 44.1 to 54.5
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 20	44.1 percentage of subjects Interval 38.9 to 49.3	45.0 percentage of subjects Interval 39.8 to 50.2
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 96	48.1 percentage of subjects Interval 42.9 to 53.3	49.1 percentage of subjects Interval 43.8 to 54.3
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 48	51.4 percentage of subjects Interval 46.1 to 56.6	49.6 percentage of subjects Interval 44.4 to 54.8
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 52	49.7 percentage of subjects Interval 44.5 to 54.9	50.1 percentage of subjects Interval 44.9 to 55.4
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 56	50.5 percentage of subjects Interval 45.3 to 55.7	50.9 percentage of subjects Interval 45.7 to 56.2
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 64	49.2 percentage of subjects Interval 44.0 to 54.4	50.7 percentage of subjects Interval 45.5 to 55.9
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 68	48.9 percentage of subjects Interval 43.7 to 54.1	50.7 percentage of subjects Interval 45.5 to 55.9
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 72	48.9 percentage of subjects Interval 43.7 to 54.1	49.3 percentage of subjects Interval 44.1 to 54.5
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 76	48.9 percentage of subjects Interval 43.7 to 54.1	49.9 percentage of subjects Interval 44.6 to 55.1
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 80	51.9 percentage of subjects Interval 46.7 to 57.1	50.1 percentage of subjects Interval 44.9 to 55.4
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 84	48.4 percentage of subjects Interval 43.2 to 53.6	49.6 percentage of subjects Interval 44.4 to 54.8
Percentage of Subjects With BCVA of 73 Letters Read or More at Each Visit - Study Eye Week 88	50.5 percentage of subjects Interval 45.3 to 55.7	50.7 percentage of subjects Interval 45.5 to 55.9

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using Spectral-Domain Optical Coherence Tomography (SD-OCT), a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 4	-160.7 micrometers Standard Deviation 126.55	-149.2 micrometers Standard Deviation 111.60
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 8	-181.8 micrometers Standard Deviation 142.11	-159.6 micrometers Standard Deviation 120.93
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 12	-190.5 micrometers Standard Deviation 148.05	-167.6 micrometers Standard Deviation 123.66
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 16	-170.9 micrometers Standard Deviation 152.48	-137.7 micrometers Standard Deviation 136.76
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 20	-161.0 micrometers Standard Deviation 151.81	-165.3 micrometers Standard Deviation 132.70
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 24	-177.8 micrometers Standard Deviation 150.62	-137.3 micrometers Standard Deviation 139.32
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 28	-182.7 micrometers Standard Deviation 156.04	-166.6 micrometers Standard Deviation 138.22
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 32	-168.9 micrometers Standard Deviation 157.61	-142.6 micrometers Standard Deviation 135.87
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 36	-192.6 micrometers Standard Deviation 156.51	-170.2 micrometers Standard Deviation 131.42
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 40	-183.4 micrometers Standard Deviation 156.83	-146.5 micrometers Standard Deviation 142.69
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 44	-183.8 micrometers Standard Deviation 161.42	-172.7 micrometers Standard Deviation 135.06
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 48	-189.8 micrometers Standard Deviation 158.35	-147.8 micrometers Standard Deviation 144.97
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 52	-193.8 micrometers Standard Deviation 157.22	-173.9 micrometers Standard Deviation 134.84
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 56	-184.9 micrometers Standard Deviation 162.66	-149.9 micrometers Standard Deviation 145.37
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 60	-195.4 micrometers Standard Deviation 161.34	-172.2 micrometers Standard Deviation 136.58
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 64	-190.9 micrometers Standard Deviation 160.06	-153.1 micrometers Standard Deviation 144.45
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 68	-188.4 micrometers Standard Deviation 161.63	-172.9 micrometers Standard Deviation 136.76
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 72	-192.3 micrometers Standard Deviation 160.70	-153.1 micrometers Standard Deviation 145.02
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 76	-193.1 micrometers Standard Deviation 162.00	-173.1 micrometers Standard Deviation 138.96
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 80	-188.2 micrometers Standard Deviation 165.90	-155.6 micrometers Standard Deviation 147.09
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 84	-196.2 micrometers Standard Deviation 161.97	-173.4 micrometers Standard Deviation 142.11
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 88	-192.7 micrometers Standard Deviation 162.46	-158.3 micrometers Standard Deviation 147.24
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 92	-194.9 micrometers Standard Deviation 162.35	-173.9 micrometers Standard Deviation 142.30
Change From Baseline in Central Subfield Thickness (CSFT) at Each Post-baseline Visit - Study Eye Change from baseline at Week 96	-193.6 micrometers Standard Deviation 163.97	-159.3 micrometers Standard Deviation 146.26

SECONDARY outcome

Timeframe: Baseline, Weeks 36, 40, 44, 48

Population: FAS - LOCF

CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Average Change From Baseline in CSFT Over the Period Week 36 Through Week 48 - Study Eye	-187.4 micrometers Standard Deviation 155.58	-159.3 micrometers Standard Deviation 135.92

SECONDARY outcome

Timeframe: Baseline, Weeks 84, 88, 92, 96

Population: FAS - LOCF

CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Average Change From Baseline in CSFT Over the Period Week 84 Through Week 96 - Study Eye	-194.3 micrometers Standard Deviation 161.24	-166.2 micrometers Standard Deviation 142.81

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

CSFT (the average retinal thickness of the circular area within 1 millimeter diameter around the foveal center) was assessed using SD-OCT, a non-invasive measurement which produces cross-sectional and 3-dimensional images of the eye. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Average Change From Baseline in CSFT Over the Period Week 4 Through Week 48/96 - Study Eye Change from baseline over the period Week 4 to 48	-178.7 micrometers Standard Deviation 145.33	-155.3 micrometers Standard Deviation 126.83
Average Change From Baseline in CSFT Over the Period Week 4 Through Week 48/96 - Study Eye Change from baseline over the period Week 4 to 96	-185.4 micrometers Standard Deviation 151.35	-159.7 micrometers Standard Deviation 131.74

SECONDARY outcome

Timeframe: Baseline, Weeks 12, 48, 96

Population: FAS - LOCF

CNV lesion size (the area of new blood vessels in the choroid layer of the retina) size was measured using fluorescein angiography (FA). A negative change value indicates a reduction in lesion size, whereas a positive change value indicates an increase. An increase in CNV lesion size may indicate progression of the underlying disease. Only one eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Change From Baseline in Choroidal Neovascularization (CNV) Lesion Size at Week 12, Week 48, and Week 96 - Study Eye Change from baseline at Week 12	-2.2 millimeters squared Standard Deviation 2.71	-2.5 millimeters squared Standard Deviation 4.02
Change From Baseline in Choroidal Neovascularization (CNV) Lesion Size at Week 12, Week 48, and Week 96 - Study Eye Change from baseline at Week 48	-2.3 millimeters squared Standard Deviation 2.76	-2.5 millimeters squared Standard Deviation 4.04
Change From Baseline in Choroidal Neovascularization (CNV) Lesion Size at Week 12, Week 48, and Week 96 - Study Eye Change from baseline at Week 96	-2.5 millimeters squared Standard Deviation 2.77	-2.7 millimeters squared Standard Deviation 4.03

SECONDARY outcome

Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

CSFTns was assessed using SD-OCT. A negative change value indicates an improvement, while a positive change value indicates a worsening. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 4	-51.7 micrometers Standard Deviation 91.79	-44.2 micrometers Standard Deviation 80.37
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 8	-55.0 micrometers Standard Deviation 94.92	-45.4 micrometers Standard Deviation 84.99
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 12	-52.7 micrometers Standard Deviation 96.89	-42.4 micrometers Standard Deviation 85.48
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 16	-50.5 micrometers Standard Deviation 98.30	-41.2 micrometers Standard Deviation 84.78
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 20	-49.2 micrometers Standard Deviation 95.87	-48.1 micrometers Standard Deviation 88.08
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 24	-53.4 micrometers Standard Deviation 98.35	-41.8 micrometers Standard Deviation 90.17
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 28	-56.4 micrometers Standard Deviation 99.86	-47.3 micrometers Standard Deviation 87.90
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 32	-49.8 micrometers Standard Deviation 99.41	-42.0 micrometers Standard Deviation 90.50
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 36	-59.1 micrometers Standard Deviation 101.18	-47.8 micrometers Standard Deviation 89.64
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 40	-55.9 micrometers Standard Deviation 100.01	-43.2 micrometers Standard Deviation 91.94
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 44	-56.2 micrometers Standard Deviation 106.65	-47.1 micrometers Standard Deviation 90.03
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 48	-54.8 micrometers Standard Deviation 100.28	-41.8 micrometers Standard Deviation 93.99
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 52	-58.4 micrometers Standard Deviation 102.35	-49.1 micrometers Standard Deviation 90.31
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 56	-57.3 micrometers Standard Deviation 100.85	-45.8 micrometers Standard Deviation 91.95
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 60	-60.3 micrometers Standard Deviation 100.56	-49.3 micrometers Standard Deviation 90.52
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 64	-58.0 micrometers Standard Deviation 100.89	-47.5 micrometers Standard Deviation 92.59
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 68	-56.7 micrometers Standard Deviation 100.16	-49.5 micrometers Standard Deviation 91.20
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 72	-58.6 micrometers Standard Deviation 101.34	-47.3 micrometers Standard Deviation 92.25
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 76	-59.7 micrometers Standard Deviation 101.61	-50.2 micrometers Standard Deviation 91.51
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 80	-57.8 micrometers Standard Deviation 102.92	-47.6 micrometers Standard Deviation 92.34
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 84	-60.4 micrometers Standard Deviation 102.80	-50.6 micrometers Standard Deviation 92.57
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 88	-59.7 micrometers Standard Deviation 101.97	-49.1 micrometers Standard Deviation 94.52
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 92	-60.1 micrometers Standard Deviation 102.00	-51.0 micrometers Standard Deviation 91.79
Change From Baseline in Central Subfield Neurosensory Retinal Thickness (CSFTns) at Each Post-baseline Visit - Study Eye Change from baseline at Week 96	-58.9 micrometers Standard Deviation 102.48	-49.4 micrometers Standard Deviation 94.86

SECONDARY outcome

Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

Subretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal fluid is an indicator of underlying disease. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 36	13.5 percentage of subjects Interval 10.2 to 17.4	21.7 percentage of subjects Interval 17.6 to 26.2
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 4	29.2 percentage of subjects Interval 24.6 to 34.1	36.9 percentage of subjects Interval 31.9 to 42.0
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 8	14.1 percentage of subjects Interval 10.7 to 18.0	22.8 percentage of subjects Interval 18.6 to 27.4
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 12	13.5 percentage of subjects Interval 10.2 to 17.4	20.6 percentage of subjects Interval 16.6 to 25.1
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 16	21.1 percentage of subjects Interval 17.0 to 25.6	35.5 percentage of subjects Interval 30.6 to 40.6
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 20	25.1 percentage of subjects Interval 20.8 to 29.9	22.5 percentage of subjects Interval 18.3 to 27.1
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 24	17.3 percentage of subjects Interval 13.6 to 21.5	36.9 percentage of subjects Interval 31.9 to 42.0
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 28	15.9 percentage of subjects Interval 12.4 to 20.1	22.0 percentage of subjects Interval 17.8 to 26.5
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 32	24.1 percentage of subjects Interval 19.8 to 28.7	34.4 percentage of subjects Interval 29.6 to 39.5
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 40	18.1 percentage of subjects Interval 14.3 to 22.4	33.9 percentage of subjects Interval 29.1 to 39.0
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 44	23.8 percentage of subjects Interval 19.5 to 28.5	21.7 percentage of subjects Interval 17.6 to 26.2
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 48	17.6 percentage of subjects Interval 13.8 to 21.8	33.9 percentage of subjects Interval 29.1 to 39.0
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 52	19.7 percentage of subjects Interval 15.8 to 24.2	22.8 percentage of subjects Interval 18.6 to 27.4
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 56	24.3 percentage of subjects Interval 20.0 to 29.0	33.6 percentage of subjects Interval 28.8 to 38.7
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 60	20.0 percentage of subjects Interval 16.0 to 24.4	24.4 percentage of subjects Interval 20.1 to 29.1
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 64	20.3 percentage of subjects Interval 16.3 to 24.7	35.5 percentage of subjects Interval 30.6 to 40.6
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 68	23.2 percentage of subjects Interval 19.0 to 27.9	23.6 percentage of subjects Interval 19.3 to 28.2
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 72	17.8 percentage of subjects Interval 14.1 to 22.1	34.7 percentage of subjects Interval 29.8 to 39.8
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 76	21.6 percentage of subjects Interval 17.5 to 26.2	23.0 percentage of subjects Interval 18.8 to 27.7
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 80	22.7 percentage of subjects Interval 18.5 to 27.3	33.9 percentage of subjects Interval 29.1 to 39.0
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 84	18.9 percentage of subjects Interval 15.1 to 23.3	24.7 percentage of subjects Interval 20.3 to 29.4
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 88	19.7 percentage of subjects Interval 15.8 to 24.2	31.7 percentage of subjects Interval 27.0 to 36.7
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 92	17.3 percentage of subjects Interval 13.6 to 21.5	22.8 percentage of subjects Interval 18.6 to 27.4
Percentage of Subjects With Presence of Subretinal Fluid at Each Post-baseline Visit - Study Eye Week 96	15.7 percentage of subjects Interval 12.1 to 19.8	30.4 percentage of subjects Interval 25.7 to 35.3

SECONDARY outcome

Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

Intraretinal fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal fluid is an indicator of underlying disease. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 52	9.2 percentage of subjects Interval 6.4 to 12.6	7.6 percentage of subjects Interval 5.1 to 10.8
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 76	9.2 percentage of subjects Interval 6.4 to 12.6	8.4 percentage of subjects Interval 5.8 to 11.7
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 4	10.3 percentage of subjects Interval 7.4 to 13.8	8.4 percentage of subjects Interval 5.8 to 11.7
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 8	7.0 percentage of subjects Interval 4.6 to 10.1	8.7 percentage of subjects Interval 6.0 to 12.0
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 12	7.6 percentage of subjects Interval 5.1 to 10.8	8.7 percentage of subjects Interval 6.0 to 12.0
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 16	12.7 percentage of subjects Interval 9.5 to 16.5	11.9 percentage of subjects Interval 8.8 to 15.7
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 20	16.5 percentage of subjects Interval 12.9 to 20.7	7.9 percentage of subjects Interval 5.3 to 11.1
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 24	10.5 percentage of subjects Interval 7.6 to 14.1	13.0 percentage of subjects Interval 9.7 to 16.9
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 28	9.2 percentage of subjects Interval 6.4 to 12.6	6.0 percentage of subjects Interval 3.8 to 8.9
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 32	14.3 percentage of subjects Interval 10.9 to 18.3	14.1 percentage of subjects Interval 10.7 to 18.1
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 36	7.0 percentage of subjects Interval 4.6 to 10.1	8.4 percentage of subjects Interval 5.8 to 11.7
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 40	13.2 percentage of subjects Interval 10.0 to 17.1	13.8 percentage of subjects Interval 10.5 to 17.8
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 44	12.4 percentage of subjects Interval 9.2 to 16.2	8.1 percentage of subjects Interval 5.6 to 11.4
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 48	11.1 percentage of subjects Interval 8.1 to 14.7	12.5 percentage of subjects Interval 9.3 to 16.3
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 56	13.0 percentage of subjects Interval 9.7 to 16.8	13.6 percentage of subjects Interval 10.2 to 17.5
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 60	8.4 percentage of subjects Interval 5.8 to 11.7	8.4 percentage of subjects Interval 5.8 to 11.7
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 64	10.3 percentage of subjects Interval 7.4 to 13.8	11.7 percentage of subjects Interval 8.6 to 15.4
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 68	11.1 percentage of subjects Interval 8.1 to 14.7	8.1 percentage of subjects Interval 5.6 to 11.4
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 72	11.1 percentage of subjects Interval 8.1 to 14.7	10.6 percentage of subjects Interval 7.6 to 14.2
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 80	12.4 percentage of subjects Interval 9.2 to 16.2	12.2 percentage of subjects Interval 9.0 to 16.0
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 84	10.5 percentage of subjects Interval 7.6 to 14.1	9.2 percentage of subjects Interval 6.5 to 12.6
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 88	10.8 percentage of subjects Interval 7.8 to 14.4	10.6 percentage of subjects Interval 7.6 to 14.2
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 92	10.8 percentage of subjects Interval 7.8 to 14.4	6.8 percentage of subjects Interval 4.4 to 9.8
Percentage of Subjects With Presence of Intraretinal Fluid at Each Post-baseline Visit - Study Eye Week 96	10.8 percentage of subjects Interval 7.8 to 14.4	10.3 percentage of subjects Interval 7.4 to 13.9

SECONDARY outcome

Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

Sub-retinal pigment epithelium (RPE) fluid was assessed using SD-OCT and recorded as Present/Absent. The presence of sub-RPE fluid is an indicator of underlying disease. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 16	15.9 percentage of subjects Interval 12.4 to 20.1	23.8 percentage of subjects Interval 19.6 to 28.5
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 20	17.3 percentage of subjects Interval 13.6 to 21.5	16.0 percentage of subjects Interval 12.4 to 20.1
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 36	13.2 percentage of subjects Interval 10.0 to 17.1	18.7 percentage of subjects Interval 14.9 to 23.1
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 40	15.4 percentage of subjects Interval 11.9 to 19.5	21.4 percentage of subjects Interval 17.3 to 26.0
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 4	18.1 percentage of subjects Interval 14.3 to 22.4	21.7 percentage of subjects Interval 17.6 to 26.2
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 8	16.2 percentage of subjects Interval 12.6 to 20.4	18.7 percentage of subjects Interval 14.9 to 23.1
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 12	15.9 percentage of subjects Interval 12.4 to 20.1	17.6 percentage of subjects Interval 13.9 to 21.9
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 24	10.5 percentage of subjects Interval 7.6 to 14.1	18.4 percentage of subjects Interval 14.6 to 22.8
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 28	13.8 percentage of subjects Interval 10.4 to 17.7	15.7 percentage of subjects Interval 12.2 to 19.8
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 32	18.1 percentage of subjects Interval 14.3 to 22.4	23.3 percentage of subjects Interval 19.1 to 28.0
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 44	14.9 percentage of subjects Interval 11.4 to 18.9	14.4 percentage of subjects Interval 10.9 to 18.4
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 48	13.0 percentage of subjects Interval 9.7 to 16.8	22.0 percentage of subjects Interval 17.8 to 26.5
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 52	17.3 percentage of subjects Interval 13.6 to 21.5	19.0 percentage of subjects Interval 15.1 to 23.3
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 56	19.7 percentage of subjects Interval 15.8 to 24.2	24.9 percentage of subjects Interval 20.6 to 29.7
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 60	15.9 percentage of subjects Interval 12.4 to 20.1	21.7 percentage of subjects Interval 17.6 to 26.2
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 64	19.2 percentage of subjects Interval 15.3 to 23.6	24.1 percentage of subjects Interval 19.8 to 28.8
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 68	18.1 percentage of subjects Interval 14.3 to 22.4	23.3 percentage of subjects Interval 19.1 to 28.0
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 72	17.0 percentage of subjects Interval 13.3 to 21.3	23.8 percentage of subjects Interval 19.6 to 28.5
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 76	16.5 percentage of subjects Interval 12.9 to 20.7	22.0 percentage of subjects Interval 17.8 to 26.5
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 80	21.1 percentage of subjects Interval 17.0 to 25.6	27.6 percentage of subjects Interval 23.1 to 32.5
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 84	23.2 percentage of subjects Interval 19.0 to 27.9	24.7 percentage of subjects Interval 20.3 to 29.4
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 88	21.9 percentage of subjects Interval 17.8 to 26.5	26.8 percentage of subjects Interval 22.4 to 31.7
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 92	17.3 percentage of subjects Interval 13.6 to 21.5	23.0 percentage of subjects Interval 18.8 to 27.7
Percentage of Subjects With Presence of Sub-retinal Pigment Epithelium (RPE) Fluid at Each Post-baseline Visit - Study Eye Week 96	16.5 percentage of subjects Interval 12.9 to 20.7	22.5 percentage of subjects Interval 18.3 to 27.1

SECONDARY outcome

Timeframe: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96

Population: FAS - LOCF

Subretinal fluid and intraretinal fluid were assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal and/or intraretinal fluid is an indicator of underlying disease. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 48	25.9 percentage of subjects Interval 21.6 to 30.7	43.6 percentage of subjects Interval 38.5 to 48.9
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 24	25.7 percentage of subjects Interval 21.3 to 30.4	45.3 percentage of subjects Interval 40.1 to 50.5
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 28	23.8 percentage of subjects Interval 19.5 to 28.5	27.4 percentage of subjects Interval 22.9 to 32.2
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 32	34.6 percentage of subjects Interval 29.8 to 39.7	43.9 percentage of subjects Interval 38.8 to 49.1
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 36	19.5 percentage of subjects Interval 15.5 to 23.9	28.5 percentage of subjects Interval 23.9 to 33.4
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 40	28.4 percentage of subjects Interval 23.8 to 33.3	44.4 percentage of subjects Interval 39.3 to 49.7
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 44	33.0 percentage of subjects Interval 28.2 to 38.0	29.3 percentage of subjects Interval 24.7 to 34.2
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 12	19.2 percentage of subjects Interval 15.3 to 23.6	27.6 percentage of subjects Interval 23.1 to 32.5
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 16	29.7 percentage of subjects Interval 25.1 to 34.7	44.7 percentage of subjects Interval 39.6 to 49.9
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 64	28.4 percentage of subjects Interval 23.8 to 33.3	43.4 percentage of subjects Interval 38.2 to 48.6
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 68	31.9 percentage of subjects Interval 27.2 to 36.9	30.6 percentage of subjects Interval 26.0 to 35.6
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 76	29.5 percentage of subjects Interval 24.9 to 34.4	29.8 percentage of subjects Interval 25.2 to 34.8
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 80	32.7 percentage of subjects Interval 27.9 to 37.7	42.5 percentage of subjects Interval 37.4 to 47.8
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 84	27.3 percentage of subjects Interval 22.8 to 32.1	31.4 percentage of subjects Interval 26.7 to 36.4
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 92	25.7 percentage of subjects Interval 21.3 to 30.4	28.2 percentage of subjects Interval 23.6 to 33.1
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 96	24.6 percentage of subjects Interval 20.3 to 29.3	38.2 percentage of subjects Interval 33.2 to 43.4
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 4	35.9 percentage of subjects Interval 31.1 to 41.1	42.8 percentage of subjects Interval 37.7 to 48.0
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 8	20.3 percentage of subjects Interval 16.3 to 24.7	29.3 percentage of subjects Interval 24.7 to 34.2
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 88	28.4 percentage of subjects Interval 23.8 to 33.3	38.8 percentage of subjects Interval 33.8 to 43.9
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 20	37.8 percentage of subjects Interval 32.9 to 43.0	29.8 percentage of subjects Interval 25.2 to 34.8
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 52	27.0 percentage of subjects Interval 22.6 to 31.9	29.5 percentage of subjects Interval 24.9 to 34.5
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 56	34.3 percentage of subjects Interval 29.5 to 39.4	43.1 percentage of subjects Interval 38.0 to 48.3
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 60	26.8 percentage of subjects Interval 22.3 to 31.6	32.0 percentage of subjects Interval 27.2 to 37.0
Percentage of Subjects With Presence of Subretinal and/or Intraretinal Fluid (Central Subfield) at Each Post-baseline Visit - Study Eye Week 72	27.0 percentage of subjects Interval 22.6 to 31.9	41.5 percentage of subjects Interval 36.4 to 46.7

SECONDARY outcome

Timeframe: Week 16

Population: FAS - 'efficacy/safety' approach. Censored data attributable to lack of efficacy and/or safety are imputed with q8w need = Yes at the next disease activity assessment visit.

A disease activity assessment (DAA) was performed to identify q8 treatment need. 95% confidence interval (CI) for binomial proportions is based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis. Hypothesis testing not pre-specified.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With Disease Activity Present (q8 Treatment Need = "Yes") at Week 16 - Study Eye	22.8 percentage of subjects Interval 18.6 to 27.5	32.1 percentage of subjects Interval 27.3 to 37.2

SECONDARY outcome

Timeframe: Baseline, Weeks 24, 48, 72, 96

Population: FAS - Observed. Number analyzed is the number of subjects with a value for both baseline and the specific post-baseline visit.

The National Eye Institute Visual Function Questionnaire-25 (VFQ-25) is a validated questionnaire that collects 25 vision-targeted responses from AMD subjects. The 25 questions pertain to global vision rating (1), difficulty with near vision activities (3), difficulty with distance vision activities (3), limitations in social functioning due to vision (2), role limitations due to vision (2), dependency on others due to vision (3), mental health symptoms due to vision (4), driving difficulties (3), limitations with peripheral (1) and color vision (1), and ocular pain (2). Each response is converted to a 0 to 100 sub-scale, with the lowest and highest possible scores set at 0 and 100 points, respectively. The overall composite score (0 to 100) is obtained by averaging the 25 sub-scale scores. A high score represents better functioning.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Score at Week 24, Week 48, Week 72, and Week 96 Change from baseline at Week 48	4.8 score on a scale Standard Deviation 11.57	3.6 score on a scale Standard Deviation 11.88
Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Score at Week 24, Week 48, Week 72, and Week 96 Change from baseline at Week 72	5.0 score on a scale Standard Deviation 13.38	3.2 score on a scale Standard Deviation 12.30
Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Score at Week 24, Week 48, Week 72, and Week 96 Change from baseline at Week 96	3.8 score on a scale Standard Deviation 14.06	2.6 score on a scale Standard Deviation 13.11
Change From Baseline in Visual Function Questionnaire (VFQ-25) Composite Score at Week 24, Week 48, Week 72, and Week 96 Change from baseline at Week 24	3.9 score on a scale Standard Deviation 10.09	3.5 score on a scale Standard Deviation 10.95

SECONDARY outcome

Timeframe: Week 48

Population: Safety Analysis Set - Observed

Serum samples were collected and assessed for anti-drug antibody status. Subjects were categorized as ADA negative when one of the following was met: ADA negative at all time points (predose and postdose); ADA negative at predose and no titer values above 10 at all other time points; or ADA titer of 10 at predose but negative at all other time points. ADA induced was defined as ADA negative at predose with postdose titer value greater than or equal to a titer of 30 at any timepoint. ADA boosted was defined as ADA positive at predose with postdose titer values that increased by at least two dilutions (9-fold) from their respective predose value at any time point.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With Induced or Boosted Anti-drug Antibody (ADA) Status at Week 48 (Brolucizumab Only)	18.8 percentage of subjects	—

SECONDARY outcome

Timeframe: Baseline, Weeks 12, 48, 96

Population: FAS with non-missing values. Number Analyzed represents the number of subjects with a value for both baseline and the specific post-baseline visit.

Intraretinal hemorrhage was assessed using SD-OCT and recorded as Present/Absent. The presence of intraretinal hemorrhage is an indicator of underlying disease. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With Intraretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye Week 12	6.9 percentage of subjects	6.6 percentage of subjects
Percentage of Subjects With Intraretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye Week 48	4.0 percentage of subjects	5.0 percentage of subjects
Percentage of Subjects With Intraretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye Week 96	2.1 percentage of subjects	2.7 percentage of subjects

SECONDARY outcome

Timeframe: Baseline, Weeks 12, 48, 96

Population: FAS with non-missing values. Number Analyzed represents the number of subjects with a value for both baseline and the specific post-baseline visit.

Subretinal hemorrhage was assessed using SD-OCT and recorded as Present/Absent. The presence of subretinal hemorrhage is an indicator of underlying disease. 95% confidence interval (CI) for binomial proportions was based on Clopper-Pearson exact method. One eye (study eye) contributed to the analysis.

Outcome measures

Measure	Brolucizumab 6 mg n=370 Participants Single IVT injection of brolucizumab at Day 0, Week 4, and Week 8, followed by q8w/q12w maintenance regimen until study exit	Aflibercept 2 mg n=369 Participants Single IVT injection of aflibercept at Day 0, Week 4, and Week 8, followed by q8w maintenance regimen until study exit
Percentage of Subjects With Subretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye Week 12	0.6 percentage of subjects	1.2 percentage of subjects
Percentage of Subjects With Subretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye Week 48	0.6 percentage of subjects	0.3 percentage of subjects
Percentage of Subjects With Subretinal Hemorrhage (Central Subfield) Present at the Visit While Absent at Baseline at Each Treatment - Study Eye Week 96	0.0 percentage of subjects	0.0 percentage of subjects

Adverse Events

Brolucizumab 6mg

Serious events: 79 serious events

Other events: 176 other events

Deaths: 4 deaths

Aflibercept 2mg

Serious events: 89 serious events

Other events: 194 other events

Deaths: 7 deaths

Serious adverse events

Measure	Brolucizumab 6mg n=370 participants at risk All subjects exposed to brolucizumab ophthalmic solution administered as a 6 mg/50 microliter (μL) dose	Aflibercept 2mg n=369 participants at risk All subjects exposed to aflibercept ophthalmic solution administered as a 2 mg/50 μL dose
Psychiatric disorders Depression	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Psychiatric disorders Mental fatigue	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Psychiatric disorders Mood disorder due to a general medical condition	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Psychiatric disorders Paranoid personality disorder	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Renal and urinary disorders Acute prerenal failure	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Renal and urinary disorders Haematuria	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Renal and urinary disorders Nephrolithiasis	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Renal and urinary disorders Renal failure	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Renal and urinary disorders Urinary bladder polyp	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Renal and urinary disorders Urinary bladder rupture	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Reproductive system and breast disorders Benign prostatic hyperplasia	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Reproductive system and breast disorders Postmenopausal haemorrhage	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Respiratory, thoracic and mediastinal disorders Acute pulmonary oedema	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Blood and lymphatic system disorders Anaemia	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Blood and lymphatic system disorders Iron deficiency anaemia	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Blood and lymphatic system disorders Thrombocytopenia	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Acute myocardial infarction	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Angina pectoris	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Arrhythmia	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.54% 2/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Atrial fibrillation	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Atrial flutter	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Atrioventricular block first degree	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Bundle branch block left	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Bundle branch block right	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Cardiac arrest	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Cardiac failure	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.54% 2/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Cardiac failure congestive	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Cardiopulmonary failure	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Myocardial infarction	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Myocardial ischaemia	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Parasystole	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Cardiac disorders Tachycardia	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Ear and labyrinth disorders Vertigo	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Anterior chamber inflammation - Study eye	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Blindness - Study eye	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Dry age-related macular degeneration - Study eye	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Retinal artery embolism - Study eye	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Retinal artery occlusion - Study eye	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Retinal artery thrombosis - Study eye	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Retinal detachment - Study eye	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Retinal pigment epithelial tear - Study eye	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Retinal tear - Study eye	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Uveitis - Study eye	0.81% 3/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Visual acuity reduced - Study eye	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Abdominal pain	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Colitis	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Duodenitis haemorrhagic	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Dyspepsia	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Dysphagia	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Gastritis haemorrhagic	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Gastrointestinal inflammation	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Haemorrhoids	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Inguinal hernia	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Intestinal polyp	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Large intestine perforation	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Lumbar hernia	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Pancreatitis	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Rectal haemorrhage	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Rectal prolapse	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Gastrointestinal disorders Vomiting	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
General disorders Cyst	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
General disorders Death	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.81% 3/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
General disorders Pyrexia	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Hepatobiliary disorders Bile duct stone	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Hepatobiliary disorders Biliary colic	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Hepatobiliary disorders Cholecystitis acute	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Hepatobiliary disorders Cholelithiasis	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Hepatobiliary disorders Drug-induced liver injury	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Immune system disorders Allergy to arthropod sting	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Immune system disorders Hypersensitivity	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Appendicitis	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Bacterial infection	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Bronchitis	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.54% 2/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Cytomegalovirus infection	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Dacryocystitis - Study eye	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Diverticulitis	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Endophthalmitis - Study eye	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Gastroenteritis	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Infective exacerbation of chronic obstructive airways disease	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Intervertebral discitis	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Lower respiratory tract infection	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Lung infection	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Pharyngitis	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Pneumonia	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	2.2% 8/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Respiratory tract infection	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Sepsis	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Skin infection	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Urinary tract infection	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Urosepsis	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Cataract traumatic - Study eye	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Chest injury	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Facial bones fracture	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Fall	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.54% 2/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Femoral neck fracture	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.54% 2/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Femur fracture	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Foot fracture	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Head injury	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Humerus fracture	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.54% 2/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Incisional hernia	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Injury	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Joint dislocation	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Limb traumatic amputation	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Lower limb fracture	0.81% 3/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Post procedural haematoma	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Procedural haemorrhage	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Radius fracture	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Rib fracture	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Spinal fracture	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Sternal fracture	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Tendon rupture	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Thermal burn	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Tibia fracture	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Injury, poisoning and procedural complications Toxicity to various agents	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Investigations Investigation	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Metabolism and nutrition disorders Hyperkalaemia	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Metabolism and nutrition disorders Malnutrition	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Metabolism and nutrition disorders Vitamin D deficiency	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Musculoskeletal and connective tissue disorders Arthralgia	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Musculoskeletal and connective tissue disorders Intervertebral disc protrusion	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Musculoskeletal and connective tissue disorders Osteoarthritis	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.54% 2/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Musculoskeletal and connective tissue disorders Osteoporosis	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Musculoskeletal and connective tissue disorders Polyarthritis	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Musculoskeletal and connective tissue disorders Spinal column stenosis	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Adenocarcinoma gastric	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast cancer	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Breast neoplasm	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon cancer	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colon neoplasm	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Diffuse large B-cell lymphoma	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Endometrial cancer	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Gastrointestinal carcinoma	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lung neoplasm	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Malignant melanoma	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Meningioma	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to central nervous system	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to peritoneum	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic neoplasm	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Neoplasm	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Non-small cell lung cancer	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Oesophageal carcinoma	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of lung	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Thyroid adenoma	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Carotid artery stenosis	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Cerebral haemorrhage	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Cerebral infarction	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Cerebral ischaemia	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Cerebrovascular accident	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	1.1% 4/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Cerebrovascular disorder	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.54% 2/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Ischaemic stroke	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Migraine	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Myasthenia gravis	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Radiculopathy	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Syncope	0.81% 3/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.54% 2/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Transient ischaemic attack	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.54% 2/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Nervous system disorders Vertebrobasilar insufficiency	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Psychiatric disorders Charles Bonnet syndrome	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Respiratory, thoracic and mediastinal disorders Pleurisy	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.54% 2/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	0.54% 2/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Respiratory, thoracic and mediastinal disorders Respiratory arrest	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Skin and subcutaneous tissue disorders Neuropathic ulcer	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Skin and subcutaneous tissue disorders Skin necrosis	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Surgical and medical procedures Hip surgery	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Surgical and medical procedures Implantable defibrillator replacement	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Surgical and medical procedures Varicose vein operation	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Vascular disorders Haemorrhage	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Vascular disorders Hypertensive crisis	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Vascular disorders Hypotension	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Vascular disorders Peripheral ischaemia	0.00% 0/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.27% 1/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Vascular disorders Varicose vein	0.27% 1/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	0.00% 0/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).

Other adverse events

Measure	Brolucizumab 6mg n=370 participants at risk All subjects exposed to brolucizumab ophthalmic solution administered as a 6 mg/50 microliter (μL) dose	Aflibercept 2mg n=369 participants at risk All subjects exposed to aflibercept ophthalmic solution administered as a 2 mg/50 μL dose
Eye disorders Cataract - Fellow eye	1.9% 7/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	6.0% 22/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Cataract - Study eye	3.0% 11/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	11.7% 43/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Conjunctival haemorrhage - Study eye	4.6% 17/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	5.1% 19/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Eye pain - Study eye	3.5% 13/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	5.1% 19/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Neovascular age-related macular degeneration - Fellow eye	8.4% 31/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	8.7% 32/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Eye disorders Visual acuity reduced - Study eye	8.4% 31/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	6.8% 25/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Bronchitis	5.9% 22/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	5.4% 20/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Influenza	6.5% 24/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	7.3% 27/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Infections and infestations Nasopharyngitis	11.6% 43/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	8.4% 31/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Musculoskeletal and connective tissue disorders Back pain	4.3% 16/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	7.6% 28/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).
Vascular disorders Hypertension	7.6% 28/370 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).	6.8% 25/369 • First treatment through study completion, an average of 96 weeks. Adverse Events (AE) were obtained through solicited and spontaneous comments from subjects and through observations by the Investigator as outlined in the study protocol. This analysis population includes all subjects who received at least 1 IVT injection (Safety Analysis Set).

Additional Information

Study Director

Novartis Pharmaceuticals

Phone: 1-862-778-8300

Email: novartis.email@novartis.com

Results disclosure agreements

• Principal investigator is a sponsor employee The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.
• Publication restrictions are in place

Restriction type: OTHER